Complete blood counts, liver function tests, and creatinine levels of mice on 14, 28, and 120 days after treatment with 600-μCi dose of 213Bi
| . | Age-matched control . | Day 14 . | Day 28 . | Day 120 . |
|---|---|---|---|---|
| WBC, K/μ | 6.9 ± 3.3 | 6.0 ± 0.96 | 7.1 ± 1.4 | 9.4 ± 2.3 |
| Hgb, g/dL | 15.5 ± 0.9 | 16.0 ± 0.8 | 14.2 ± 1.2 | 14.7 ± 1.2 |
| Plt, K/μL | 1090.7 ± 287.9 | 1914.4 ± 343.7 | 1163.2 ± 482.6 | 1341.3 ± 96.4 |
| ANC, K/μL | 2.74 ± 2.1 | 2.40 ± 0.7 | 3.6 ± 0.4 | 2.3 ± 0.6 |
| AST, U/L | 116.0 ± 17.6 | 194.4 ± 21.8 | 107.2 ± 8.3 | 174.3 ± 52.0 |
| ALT, U/L | 43.2 ± 4.8 | 53.6 ± 9.6 | 46.4 ± 3.6 | 52.5 ± 17.1 |
| Creatinine, mg/dL | 0.56 ± 0.2 | 0.68 ± 0.1 | 0.52 ± 0.1 | 0.58 ± 0.2 |
| . | Age-matched control . | Day 14 . | Day 28 . | Day 120 . |
|---|---|---|---|---|
| WBC, K/μ | 6.9 ± 3.3 | 6.0 ± 0.96 | 7.1 ± 1.4 | 9.4 ± 2.3 |
| Hgb, g/dL | 15.5 ± 0.9 | 16.0 ± 0.8 | 14.2 ± 1.2 | 14.7 ± 1.2 |
| Plt, K/μL | 1090.7 ± 287.9 | 1914.4 ± 343.7 | 1163.2 ± 482.6 | 1341.3 ± 96.4 |
| ANC, K/μL | 2.74 ± 2.1 | 2.40 ± 0.7 | 3.6 ± 0.4 | 2.3 ± 0.6 |
| AST, U/L | 116.0 ± 17.6 | 194.4 ± 21.8 | 107.2 ± 8.3 | 174.3 ± 52.0 |
| ALT, U/L | 43.2 ± 4.8 | 53.6 ± 9.6 | 46.4 ± 3.6 | 52.5 ± 17.1 |
| Creatinine, mg/dL | 0.56 ± 0.2 | 0.68 ± 0.1 | 0.52 ± 0.1 | 0.58 ± 0.2 |
Toxicity of pretargeted RIT with 600 μCi 213Bi in athymic mice. Hematologic, hepatic, and renal toxicities were measured at day 14, 28, and 120 in age-matched mice or mice treated with 1F5(scFv)4SA followed by NAGB CA and DOTA-biotin conjugated with 600 μCi 213Bi. The numbers are the average values of 4 mice that achieved long-term disease remissions of more than 120 days.